biostudies-literatureSriprasart TGSK133-158https://www.ebi.ac.uk/biostudies/studies/S-EPMC9859883biostudies-literatureUnknown40(1)<h4>Introduction</h4>Short-acting β₂-agonist (SABA) reliever overuse is common in asthma, despite availability of inhaled corticosteroid (ICS)-based maintenance therapies, and may be associated with increased risk of adverse events (AEs). This systematic literature review (SLR) and meta-analysis aimed to investigate the safety and tolerability of SABA reliever monotherapy for adults and adolescents with asthma, through analysis of randomized controlled trials (RCTs) and real-world evidence.<h4>Methods</h4>An SLR of English-language publications between January 1996 and December 2021 included RCTs and observational studies of patients aged ≥ 12 years treated with inhaled SABA reliever monotherapy (fixed dose or as needed) for ≥ 4 weeks. Studies of terbutaline and fenoterol were eAdvances in therapySafety of SABA Monotherapy in Asthma Management: a Systematic Review and Meta-analysis.PMC9859883Study ID 218222Roguska AAggarwal BLevy GSriprasart TGarcia GMittal LRubin AFulmali SPhansalkar AWaterer GAndrade MALMartin AfalseSafety of SABA Monotherapy in Asthma Management: a Systematic Review and Meta-analysis.<h4>Introduction</h4>Short-acting β₂-agonist (SABA) reliever overuse is common in asthma, despite availability of inhaled corticosteroid (ICS)-based maintenance therapies, and may be associated with increased risk of adverse events (AEs). This systematic literature review (SLR) and meta-analysis aimed to investigate the safety and tolerability of SABA reliever monotherapy for adults and adolescents with asthma, through analysis of randomized controlled trials (RCTs) and real-world evidence.<h4>Methods</h4>An SLR of English-language publications between January 1996 and December 2021 included RCTs and observational studies of patients aged ≥ 12 years treated with inhaled SABA reliever monotherapy (fixed dose or as needed) for ≥ 4 weeks. Studies of terbutaline and fenoterol were e2023-01-01T00:00:00Z2023 Jan2025-04-06T09:47:05.066Z2025-04-06T09:47:05.066ZS-EPMC98598833634814110.1007/s12325-022-02356-2